#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroendocrine carcinoma of the skin Demyelination Familial haemophagocytic lymphohistiocytosis Primary mediastinal large B-cell lymphoma Sexually transmitted disease Peritoneal mesothelioma malignant Dilated cardiomyopathy Leiomyosarcoma recurrent Encephalitis autoimmune Neuromyelitis optica spectrum disorder Transitional cell cancer of the renal pelvis and ureter Raynaud's phenomenon Renal cell carcinoma Mantle cell lymphoma stage II Pulmonary hypertension More trials…

    Learn about Rare Diseases

    Tuberous sclerosis complex – Trials in Disease Usher’s syndrome – Trials in Disease Ehlers-Danlos syndrome – Basic Information Haemophilia A without inhibitors – Basic Information Glomerulonephritis rapidly progressive Prolymphocytic leukaemia Antithrombin III deficiency – Diagnostics Fabry’s disease – Life with Disease Activated PI3 kinase delta syndrome – Life with Disease Pituitary-dependent Cushing’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Diltiazem Ipn01194 Tadekinig Alfa Regn5668 Sirexatamab Fluorodopa (18F) Tabelecleucel Regorafenib Pentosan Polysulfate Sodium IBUZATRELVIR Csm-Gw Secale Cereale IHMA-2121908-1 TROFOLASTAT Azd3427 HEMOPEXIN, HUMAN Camonsertib Gindameran Oxcarbazepine 177Lu-Dpi-4452 More therapies…

    Learn about Your Condition

    Ischaemic stroke HER2 positive breast cancer Cold type haemolytic anaemia Gastrointestinal disorder Behcet's syndrome Transplant rejection Biopsy heart Encephalitis Japanese B Colon cancer metastatic Melanoma recurrent Lymphocytic lymphoma Cough Schizophrenia Nicotine dependence Cardiogenic shock More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General Hospital Of Messinia

General Hospital Of Messinia

Antikalamos, Kalamata, 241 00, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • LY4170156
    • Topotecan
    Austria Belgium Czechia Denmark France Germany +9

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • AZD5335
    • Doxorubicin Hydrochloride, Liposomal
    Belgium Czechia Denmark France Germany Greece +4

  • A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Db-1303
    • Docetaxel
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark Finland France +9

  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    • Obesity
    Bulgaria Czechia Denmark France Germany Greece +4

  • A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician’s Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Doxorubicin Hydrochloride
    • Sacituzumab Govitecan
    Czechia France Germany Greece Italy Poland +1

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Insulin Glargine
    • Insulin Icodec
    • Metformin
    Greece Italy Poland

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!